Marco Weinberg

Marco Weinberg's Title

Marco Weinberg currently holds the prestigious position of Head of Research. In this role, he oversees research initiatives and strategic direction for his organization, leveraging his extensive experience in molecular biology and gene therapy. His leadership in research has been instrumental in advancing scientific knowledge and innovation.

Marco Weinberg's Education and Expertise

Marco Weinberg earned his Ph.D. in Molecular Biology from the University of the Witwatersrand, South Africa. His advanced education has provided him with a deep understanding of molecular mechanisms and therapeutic approaches, which he has applied throughout his illustrious career. His expertise in gene therapy and nucleic acid therapies is well-recognized in the scientific community.

Marco Weinberg's Previous Roles

Before his current role, Marco Weinberg served in several high-impact positions. He was the vice president of research at Asklepios BioPharmaceutical, Inc. (AskBio), where he led groundbreaking research in gene therapy. At CSL Behring, he directed gene therapy research, contributing to significant advancements in the field. He also held the position of associate director of molecular biology and nucleic acid therapies at Vertex Pharmaceuticals, further solidifying his reputation as a leader in molecular biology.

Marco Weinberg's Academic Contributions

Marco Weinberg has an impressive academic background, having held assistant and associate professorships at Scripps Research and the University of the Witwatersrand, South Africa, respectively. His academic roles have allowed him to mentor the next generation of scientists and contribute to the broader scientific community. His involvement as the associate editor of Molecular Therapy – Nucleic Acids highlights his commitment to advancing scientific knowledge and research dissemination.

Marco Weinberg's Achievements

Marco Weinberg has made significant contributions to the field of molecular biology and gene therapy. He has published more than 70 scientific papers, sharing his research findings with the global scientific community. Additionally, he holds 10 patents, reflecting his innovative work and dedication to advancing therapeutic technologies. As a co-founder and former director of Zetta Genomics, he played a key role in shaping the company's research direction and success.